- Phase3 survival
- 12.4 vs 6.7 months median overall survival
Revolution Medicines is a US oncology company developing drugs that block RAS proteins, which drive many cancers. In October 2026 EMA's human medicines committee recommended EU approval of its oral RAS inhibitor Rasonque (daraxonrasib) for previously treated metastatic pancreatic cancer, after a phased review that took under 150 days. In its Phase 3 trial, median survival was 12.4 months against 6.7 months on chemotherapy.